Zenas BioPharma, Inc. (NASDAQ:ZBIO) Receives $44.14 Consensus Target Price from Analysts

Shares of Zenas BioPharma, Inc. (NASDAQ:ZBIO) have been assigned a consensus recommendation of “Hold” from the nine analysts that are currently covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and six have given a buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $44.1429.

Several equities analysts have recently commented on the stock. Zacks Research downgraded shares of Zenas BioPharma from a “hold” rating to a “strong sell” rating in a report on Tuesday, March 17th. Jefferies Financial Group reissued a “buy” rating and issued a $48.00 price objective on shares of Zenas BioPharma in a research note on Tuesday, January 6th. Morgan Stanley lifted their price objective on shares of Zenas BioPharma from $19.00 to $21.00 and gave the stock an “equal weight” rating in a research note on Tuesday, March 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zenas BioPharma in a research note on Friday, March 27th. Finally, Wall Street Zen cut shares of Zenas BioPharma from a “hold” rating to a “strong sell” rating in a research note on Saturday, March 21st.

Zenas BioPharma Price Performance

Shares of NASDAQ:ZBIO opened at $18.19 on Monday. The company has a debt-to-equity ratio of 0.32, a current ratio of 5.61 and a quick ratio of 5.61. Zenas BioPharma has a 1-year low of $8.51 and a 1-year high of $44.60. The company has a market capitalization of $1.04 billion, a P/E ratio of -2.33 and a beta of -0.54. The firm’s 50 day simple moving average is $23.00 and its two-hundred day simple moving average is $27.28.

Zenas BioPharma (NASDAQ:ZBIO) last released its earnings results on Monday, April 13th. The company reported ($1.10) EPS for the quarter. Research analysts expect that Zenas BioPharma will post -4.97 EPS for the current fiscal year.

Insider Activity

In other news, CEO Leon O. Moulder, Jr. bought 57,000 shares of Zenas BioPharma stock in a transaction dated Monday, February 2nd. The shares were acquired at an average price of $17.96 per share, with a total value of $1,023,720.00. Following the completion of the purchase, the chief executive officer owned 423,155 shares in the company, valued at $7,599,863.80. The trade was a 15.57% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Hongbo Lu bought 3,768 shares of Zenas BioPharma stock in a transaction dated Tuesday, March 31st. The stock was purchased at an average cost of $18.63 per share, for a total transaction of $70,197.84. Following the purchase, the director owned 426,736 shares of the company’s stock, valued at approximately $7,950,091.68. This trade represents a 0.89% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders acquired 256,613 shares of company stock worth $5,178,383. Insiders own 22.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ZBIO. Polar Capital Holdings Plc purchased a new position in Zenas BioPharma in the 4th quarter worth about $38,402,000. Federated Hermes Inc. increased its position in Zenas BioPharma by 45.9% during the 4th quarter. Federated Hermes Inc. now owns 2,715,578 shares of the company’s stock valued at $98,603,000 after purchasing an additional 853,740 shares during the period. EcoR1 Capital LLC purchased a new position in Zenas BioPharma during the 4th quarter valued at about $28,667,000. NEA Management Company LLC increased its position in Zenas BioPharma by 28.9% during the 4th quarter. NEA Management Company LLC now owns 3,523,219 shares of the company’s stock valued at $127,928,000 after purchasing an additional 789,500 shares during the period. Finally, NEXTBio Capital Management LP purchased a new position in Zenas BioPharma during the 4th quarter valued at about $11,691,000.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company’s proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.